HER2 Inhibition in Gastric Cancer—Novel Therapeutic Approaches for an Established Target

SIMPLE SUMMARY: The human epidermal growth factor receptor 2 (HER2) became the first routinely targeted biomarker in the management of stomach cancers when the monoclonal antibody trastuzumab given with chemotherapy was shown to improve patient survival in 2010. Over the past decade, we have develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Fong, Caroline, Chau, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367333/
https://www.ncbi.nlm.nih.gov/pubmed/35954487
http://dx.doi.org/10.3390/cancers14153824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367333/
https://www.ncbi.nlm.nih.gov/pubmed/35954487
http://dx.doi.org/10.3390/cancers14153824

Ejemplares similares